Skip to main content
Premium Trial:

Request an Annual Quote

Lab21 Buys Fungal Molecular Diagnostics Firm Myconostica

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Lab21 today announced it has acquired fungal molecular diagnostic firm Myconostica for an undisclosed amount.

The deal will expand Lab21's portfolio of diagnostics and will provide it with its first nucleic acid-based assays. It also provides Lab21 with manufacturing capabilities to develop and produce a range of new biomarker assays, the Cambridge, UK-based firm said.

Based in Manchester, UK, Myconostica has three CE-marked tests available in Europe, Canada, and South Africa, including tests for extracting fungal DNA from human samples and tests for detecting Aspergillus and Pneumocystis jirovecii.

Lab21 will develop global sales of Myconostica's products and launch the Myconostica fungal testing service from its reference laboratory in Greenville, SC, as well as its lab in Cambridge.

The companies said that the global market for fungal testing is about 10 million patients annually.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.